Progression of tractional retinal detachment following intravitreal bevacizumab.
Jonas
Jost B
JB
Schmidbauer
Matthias
M
Rensch
Florian
F
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003922:Diabetes Mellitus, Type 1; D003930:Diabetic Retinopathy / Q000473:pathology*; D018450:Disease Progression; D005123:Eye / Q000098:blood supply; D005260:Female; D015355:Glaucoma, Neovascular / Q000517:prevention & control; D006801:Humans; D007267:Injections; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000517:prevention & control; D012163:Retinal Detachment / Q000473:pathology*; D012171:Retinal Vessels / Q000187:drug effects; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab